Valiant Laboratories Limited (VALIANTLAB) Fair Value & Analysis
Healthcare · IN · Market cap ₹3.5B
Fair value as of: Jul 3, 2026
From 6 valuation models · updated today
Share price −12.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹50.93 – ₹115.51 · fair‑value band ₹4.26 – ₹11.91 · the ₹65.01 price screens above the ₹8.09 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Valiant Laboratories Limited (VALIANTLAB) currently trades at ₹65.01, while our model-based Fair Value estimate is ₹8.09 — implying the stock looks roughly 87.6% overvalued today. We read business quality at 31/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Valiant Laboratories Limited generated revenue of ₹2.4B at a net margin of -1.4%. Revenue grew 59.2% year over year. It earns a return on equity of -1.2%. Net debt stands at ₹392M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Valiant Laboratories Limited reported revenue of ₹2.4B in FY2026 versus ₹2.9B in FY2022, a compound −5.0%/yr. Reported net income was −₹32.7M in FY2026.
Is VALIANTLAB fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Valiant Laboratories Limited (VALIANTLAB) undervalued?
What is the fair value of VALIANTLAB?
What is the quality score of VALIANTLAB?
What is the revenue of Valiant Laboratories Limited (VALIANTLAB)?
What is the net profit margin of VALIANTLAB?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.